Evoke Pharma’s Real-World Healthcare Utilization Data Comparing GIMOTI® to Oral Metoclopramide to Be Presented at Digestive Disease Week (DDW) 2023
May 04, 2023 08:30 ET
|
Evoke Pharma, Inc.
Compelling data elevated to distinguished DDW oral plenary session GIMOTI to be showcased in additional activities at conference SOLANA BEACH, Calif., May 04, 2023 (GLOBE NEWSWIRE) --...
New GIMOTI Patent Listed in FDA Orange Book
May 01, 2023 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
United States Patent and Trademark Office (USPTO) Grants Evoke Pharma a Formulation Patent Covering GIMOTI
April 20, 2023 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI-Related Patent
April 06, 2023 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., April 06, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma & EVERSANA Announce Compelling Real-World Data on the Impact of GIMOTI in Reducing the Utilization of Healthcare Resources to be Presented at the Academy of Managed Care Pharmacy (AMCP) 2023
March 23, 2023 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Reports Fourth Quarter and Full Year 2022 Financial Results
March 21, 2023 16:05 ET
|
Evoke Pharma, Inc.
Fiscal year 2022 net product sales from prescriptions increased by 179% to $2.5 million versus 2021Patient enrollment increased by 149% compared with 2021 SOLANA BEACH, Calif., March 21, 2023 ...
Evoke Pharma to Report Fourth Quarter and Full Year 2022 Results on March 21, 2023
March 15, 2023 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma and EVERSANA Selected to Present Results of Real-World Healthcare Utilization Study Comparing GIMOTI® and Oral Metoclopramide at the Digestive Disease Week Plenary Session
February 21, 2023 07:00 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti
January 30, 2023 07:00 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023
January 18, 2023 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...